^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    1d
    A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    6d
    PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC (clinicaltrials.gov)
    P1, N=396, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    Ameile (aumolertinib)
    8d
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=403 --> 167
    Enrollment closed • Enrollment change • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    10d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    15d
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • Tagrisso (osimertinib) • carboplatin • Ivesa (firmonertinib)
    22d
    AndroMETa-CRC-064: A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=74, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=460 --> 74 | Trial completion date: Oct 2028 --> Aug 2027 | Trial primary completion date: Oct 2028 --> Aug 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    27d
    Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. (clinicaltrials.gov)
    P2, N=252, Not yet recruiting, Shanghai Allink Biotherapeutics Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR expression • MET expression
    |
    Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    1m
    A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    SKB571-II-02: A Phase II Study of SKB571 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=295, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | N=190 --> 295
    Enrollment change
    1m
    Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2028 --> Dec 2027 | Trial primary completion date: Sep 2028 --> Dec 2027
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    telisotuzumab adizutecan (ABBV-400)
    1m
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=403, Recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2027 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)